Healthcare provider profile · identity verified

Mark E Hooste, MD

Family Practice · FORT BRAGG, NC · NPI 1750537205

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	497	149
Levothyroxine Sodium	Levothyroxine Sodium	270	70
Losartan Potassium	Losartan Potassium	254	69
Lisinopril	Lisinopril	232	67
Amlodipine Besylate	Amlodipine Besylate	229	71
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	202	31
Gabapentin	Gabapentin	195	59
Hydrochlorothiazide	Hydrochlorothiazide	173	54
Metformin Hcl Er	Metformin Hcl	161	45
Omeprazole	Omeprazole	146	45
Albuterol Sulfate Hfa	Albuterol Sulfate	140	42
Trazodone Hcl	Trazodone Hcl	136	36
Rosuvastatin Calcium	Rosuvastatin Calcium	125	43
Metoprolol Succinate	Metoprolol Succinate	118	32
Duloxetine Hcl	Duloxetine Hcl	116	28
Tramadol Hcl	Tramadol Hcl	111	18
Metformin Hcl	Metformin Hcl	100	27
Furosemide	Furosemide	96	26
Eliquis	Apixaban	93	27
Pravastatin Sodium	Pravastatin Sodium	91	26
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	79	25
Tamsulosin Hcl	Tamsulosin Hcl	78	26
Meloxicam	Meloxicam	75	20
Pantoprazole Sodium	Pantoprazole Sodium	73	24
Sertraline Hcl	Sertraline Hcl	69	22
Alprazolam	Alprazolam	65	18
Potassium Chloride	Potassium Chloride	65	15
Telmisartan	Telmisartan	61	19
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	58	17
Carvedilol	Carvedilol	55	17
Ozempic	Semaglutide	54	13
Simvastatin	Simvastatin	52	16
Celecoxib	Celecoxib	51	14
Fluticasone Propionate	Fluticasone Propionate	51	23
Atenolol	Atenolol	50	11
Famotidine	Famotidine	49	16
Montelukast Sodium	Montelukast Sodium	49	12
Finasteride	Finasteride	48	14
Fluoxetine Hcl	Fluoxetine Hcl	48	17
Pregabalin	Pregabalin	48	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	45	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	42	14
Glipizide	Glipizide	42	12
Allopurinol	Allopurinol	41	11
Clopidogrel	Clopidogrel Bisulfate	39	11
Trulicity	Dulaglutide	39	11
Jardiance	Empagliflozin	38	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	38	12
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	38	suppressed
Spironolactone	Spironolactone	38	18
Alendronate Sodium	Alendronate Sodium	37	12
Lorazepam	Lorazepam	37	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	36	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	35	12
Zolpidem Tartrate	Zolpidem Tartrate	34	suppressed
Fenofibrate	Fenofibrate	32	suppressed
Aripiprazole	Aripiprazole	29	suppressed
Ezetimibe	Ezetimibe	29	12
Metoprolol Tartrate	Metoprolol Tartrate	29	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	28	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	28	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	28	11
Estradiol	Estradiol	27	12
Propranolol Hcl	Propranolol Hcl	27	suppressed
Buspirone Hcl	Buspirone Hcl	25	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	25	suppressed
Diazepam	Diazepam	24	suppressed
Glipizide Er	Glipizide	24	suppressed
Bupropion Xl	Bupropion Hcl	23	suppressed
Diclofenac Sodium	Diclofenac Sodium	23	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	23	suppressed
Topiramate	Topiramate	23	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	22	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	22	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	22	suppressed
Chlorthalidone	Chlorthalidone	21	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	21	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	21	suppressed
Promethazine Hcl	Promethazine Hcl	21	suppressed
Ramipril	Ramipril	21	suppressed
Ropinirole Hcl	Ropinirole Hcl	21	suppressed
Xarelto	Rivaroxaban	21	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	20	suppressed
Baclofen	Baclofen	19	suppressed
Memantine Hcl	Memantine Hcl	19	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	19	suppressed
Symbicort	Budesonide/Formoterol Fumarate	19	suppressed
Warfarin Sodium	Warfarin Sodium	19	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	18	suppressed
Acyclovir	Acyclovir	17	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	17	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	17	suppressed
Tizanidine Hcl	Tizanidine Hcl	17	suppressed
Valacyclovir	Valacyclovir Hcl	17	suppressed
Azelastine Hcl	Azelastine Hcl	16	suppressed
Incruse Ellipta	Umeclidinium Bromide	16	suppressed
Meclizine Hcl	Meclizine Hcl	16	suppressed
Donepezil Hcl	Donepezil Hcl	15	suppressed
Levetiracetam	Levetiracetam	15	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	15	suppressed
Glimepiride	Glimepiride	14	suppressed
Testosterone Cypionate	Testosterone Cypionate	14	suppressed
Aimovig Autoinjector	Erenumab-Aooe	13	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Felodipine Er	Felodipine	13	suppressed
Methotrexate	Methotrexate Sodium	13	suppressed
Myrbetriq	Mirabegron	13	suppressed
Terazosin Hcl	Terazosin Hcl	13	suppressed
Tolterodine Tartrate	Tolterodine Tartrate	13	suppressed
Tradjenta	Linagliptin	13	suppressed
Carisoprodol	Carisoprodol	12	suppressed
Nystatin	Nystatin	12	suppressed
Ondansetron Odt	Ondansetron	12	suppressed
Oxycodone Hcl	Oxycodone Hcl	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Synthroid	Levothyroxine Sodium	12	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	12	suppressed
Breyna	Budesonide/Formoterol Fumarate	11	suppressed
Clonazepam	Clonazepam	11	suppressed
Fluconazole	Fluconazole	11	suppressed
Hydralazine Hcl	Hydralazine Hcl	11	suppressed
Ibuprofen	Ibuprofen	11	suppressed
Morphine Sulfate Er	Morphine Sulfate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error